$AVR

L1 Capital Pty Ltd sold $4.1M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 495,189 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.30 ($8.23–$8.30, $4.11M total) across 2 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 6, 2026, 10:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A large-holder open-market sale can affect sentiment, but without accompanying company news in the text, it is more likely to be a positioning signal than a fundamental reset.

02

Market read

Traders may monitor for follow-on selling or interpret the sale as a sentiment headwind, but the article does not provide new operational or financial information.

03

What to watch

Because the transaction is indirect and the filing lacks stated rationale, traders may over-weight it versus other upcoming catalysts (earnings, trial updates, financing).

Relevance 6/10Novelty 4/10Timing: filed 2026-08-06, covering sales on 2026-08-04 to 2026-08-05

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 495,189 shares of Anteris Technologies Global Corp (AVR) for about $4.11M via open-market trades.

Expected impact

Near-term impact is likely limited, with focus on whether further selling continues or if the sale is routine under a 10b5-1 plan (here, none is stated).

Evidence & confidence

Form 4 provides transaction details and size, but the article does not include earnings, contracts, regulatory actions, or other company-specific catalysts that would reprice the stock.

Market effects

No sector-level implications are provided; this is a single-issuer Form 4 transaction.

None indicated.

None indicated.

Counterpoint

The sale may be non-informational (liquidity, diversification, tax, or planned disposition), especially since the filing does not state a 10b5-1 plan but still reflects a discrete, dated window.

Key entities

  • Anteris Technologies Global Corp

    Company whose shares were sold; ticker AVR.

  • L1 Capital Pty Ltd

    Reporter of the Form 4 transaction, selling shares via indirect holdings.

  • SEC Form 4

    Primary-source disclosure of insider transaction details.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.